Revolutionary KRAS Cancer Drug Achieves 61% Response Rate in Lung Cancer Patients - Key Trial Data Released

Revolution Medicine’s KRAS drug shows potential in early cut of lung cancer data

CHICAGO — An experimental KRAS G12D drug from Revolution Medicines made waves last year as a potential treatment for pancreatic cancer. On Sunday, new results from an early data readout showed it works on lung ...

Zoldonrasib Shows Encouraging Early Antitumor Activity in KRAS G12D–Mutated NSCLC

Zoldonrasib demonstrates early promise in patients with KRAS G12D–mutated non–small cell lung cancer.

Revolutionary KRAS Cancer Drug Achieves 61% Response Rate in Lung Cancer Patients - Key Trial Data Released

New Phase 1 data reveals promising 89% disease control rate for zoldonrasib in KRAS-mutant lung cancer. See complete safety and efficacy findings.

AACR 2025: Oral Investigational Agent Zoldonrasib Elicits Objective Responses in Patients With KRAS G12D-Mutated NSCLC

Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.